Status:
COMPLETED
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to characterize the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]PF-05221304 in Healthy Adult Male Subjects
Eligibility Criteria
Inclusion
- Ages of 18 and 45 years, inclusive.
- Body mass index (BMI) of \>= 17.5 and \<= 30.4 kg/m2
- Total body weight \> 50 kg (110 lb).
Exclusion
- 1\. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, allergic disease or clinical findings.
Key Trial Info
Start Date :
April 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 13 2018
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03448172
Start Date
April 18 2018
End Date
June 13 2018
Last Update
December 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit Inc.
Madison, Wisconsin, United States, 53704